- Home
- STEP vs DNTH Comparison
STEP vs DNTH Comparison
Compare STEP & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEP | DNTH |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.6B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | STEP | DNTH |
|---|---|---|
| Price | $55.60 | $86.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $71.00 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 824.3K | 492.6K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.98% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,174,830,000.00 | $2,036,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $26.41 | $29.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 65.09 | N/A |
| 52 Week Low | $40.58 | $16.77 |
| 52 Week High | $77.80 | $96.50 |
Technical Indicators
Market Signals| Indicator | STEP | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 60.48 | 50.54 |
| Support Level | $49.48 | $82.00 |
| Resistance Level | $63.91 | $88.45 |
| Average True Range (ATR) | 2.53 | 4.42 |
| MACD | 0.11 | -0.90 |
| Stochastic Oscillator | 73.30 | 44.24 |
Price Performance
Historical ComparisonAbout STEP StepStone Group Inc.
StepStone Group Inc operates as a fully integrated private markets solution provider. The company provides customized investment solutions and advisory and data services. It provides investment solutions in the areas of private equity, real estate, private debt, and infrastructure and real assets. The company consists of a single operating segment and a single reportable segment for accounting and financial reporting purposes.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.